ArticleFrontiers in pediatrics2026
Urinary fatty acid binding protein 2 as a biomarker of intestinal injury in pediatric celiac disease.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Celiac disease (CeD) is an autoimmune enteropathy triggered by gluten in genetically predisposed individuals, causing intestinal damage and impaired gut barrier integrity. Current diagnostic methods, such as serology and intestinal biopsy, are costly and invasive. Intestinal fatty acid binding protein (FABP2), exclusively expressed in the cytosol of mature enterocytes and released during injury, offers a potential non-invasive alternative biomarker. This study aimed to evaluate urinary FABP2 levels in pediatric patients undergoing gastrointestinal assessment or CeD follow-up to determine its potential as a non-invasive biomarker of intestinal integrity. Methods: In this retrospective cross-sectional study, urinary FABP2 was measured in 103 pediatric patients evaluated for intestinal permeability using the lactulose/mannitol test. Based on serology and symptomatology, patients were categorized as controls ( Results: FABP2 levels were significantly elevated in active CeD patients (47.7 pg/mL) compared with controls (9.65 pg/mL) ( Conclusion: Our findings indicate that urinary FABP2 reflects intestinal epithelial injury and may serve as a non-invasive biomarker for assessing gut integrity and disease activity in CeD. However, larger prospective studies with histological correlation are needed to validate its diagnostic utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.